Epitope

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Retrieved on: 
Thursday, February 15, 2024

In addition, the Company provided 2024 financial guidance and business highlights.

Key Points: 
  • In addition, the Company provided 2024 financial guidance and business highlights.
  • “2023 was a year of strong progress for Prothena as we advanced our protein dysregulation portfolio and moved closer to becoming a fully integrated commercial company.
  • Total revenue for the fourth quarter and full year of 2023 included BMS collaboration revenue of $0.3 million and $91.3 million, respectively.
  • As of December 31, 2023, Prothena had $621.0 million in cash, cash equivalents and restricted cash, and no debt.

Attovia Announces Second Tranche Closing of $60 Million Series A Financing and Highlights Progress Building a Best-in-Class Pipeline Leveraging the Attobody™ Platform

Retrieved on: 
Thursday, February 8, 2024

FREMONT, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics, a biotech company pioneering spatially optimized biparatopic biologics, announced the closing of the $30 million second tranche of its previously reported $60 million Series A financing. Attovia also announced the nomination of the first development candidate generated from its Attobody™ biologics platform, ATTO-1310, a potential first-in-class, long half-life anti-IL31 Attobody. Proceeds from the second tranche will be used to advance ATTO-1310 through early clinical trials, move the Company’s second program, ATTO-002, a bispecific IL31 x IL13 ligand trap, toward IND-enabling studies, and to further develop the Attobody platform and early discovery pipeline.

Key Points: 
  • Attovia also announced the nomination of the first development candidate generated from its Attobody™ biologics platform, ATTO-1310, a potential first-in-class, long half-life anti-IL31 Attobody.
  • Proceeds from the second tranche will be used to advance ATTO-1310 through early clinical trials, move the Company’s second program, ATTO-002, a bispecific IL31 x IL13 ligand trap, toward IND-enabling studies, and to further develop the Attobody platform and early discovery pipeline.
  • In just eight months, the Attovia team has successfully closed both tranches of the $60 million Series A financing, built a pipeline of five novel programs, and rapidly advanced our lead programs towards the clinic.
  • Attovia expects to nominate a development candidate and advance the candidate to IND enabling studies in the second half of 2024.

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

Retrieved on: 
Tuesday, February 6, 2024

The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.

Key Points: 
  • The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.
  • Dr. John M. Lindner and his research team at the BioMed X Institute in Heidelberg designed the T-FINDER platform to solve this problem.
  • This work provides key insights into the mechanism of anti-tumor T cell responses in these patients and will support ongoing vaccination studies.
  • "Previously, we have been limited in the tools we could use to study class II-presented epitopes such as mutant H3.

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Retrieved on: 
Monday, January 22, 2024

“We are excited about the potential of our ground-breaking technology in neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.

Key Points: 
  • “We are excited about the potential of our ground-breaking technology in neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
  • Using a proprietary computational platform, ProMIS identified potential conformational epitopes (misfolded portions) unique to toxic alpha-synuclein involved in synucleinopathies.
  • Formulations of several of these epitopes were tested in mouse vaccination studies leading to the selection of a lead vaccine candidate for testing in mouse models replicating cognitive and motor deficits of human disease.
  • Results from the vaccination studies are being submitted for presentation at the 2024 meeting of the American Academy of Neurology (AAN) taking place from April 13-18, 2024 in Denver, Colorado.

ReiThera Srl, The Ragon Institute and IAVI Announce Collaboration to Advance Highly Networked T Cell HIV Vaccine Candidate Towards Phase I Clinical Evaluation

Retrieved on: 
Monday, January 22, 2024

ReiThera Srl, the Ragon Institute of Mass General, MIT, and Harvard, and IAVI are pleased to announce a collaboration to develop a novel HIV vaccine candidate that will be composed of ReiThera’s GRAd vector and HIV T cell epitopes identified by the Ragon Institute, funded by the Bill & Melinda Gates Foundation.

Key Points: 
  • ReiThera Srl, the Ragon Institute of Mass General, MIT, and Harvard, and IAVI are pleased to announce a collaboration to develop a novel HIV vaccine candidate that will be composed of ReiThera’s GRAd vector and HIV T cell epitopes identified by the Ragon Institute, funded by the Bill & Melinda Gates Foundation.
  • The Ragon Institute will lead GRAd-HIV preclinical development.
  • IAVI will be the sponsor and execute a phase I clinical trial to evaluate the safety and immunogenicity of the GRAd-HIV vaccine candidate.
  • Stefano Colloca, ReiThera’s Chief Technology Officer and co-Founder, said,
    “We look forward to collaborating with IAVI and the Ragon Institute and continuing to advance our shared vaccine commitment to address the global challenges posed by HIV.

iBio Announces Participation in 23rd Annual PepTalk Conference

Retrieved on: 
Tuesday, January 16, 2024

He will also moderate a BuzZ talk on the topic as part of the conference's "Developability of Bispecifics" program .

Key Points: 
  • He will also moderate a BuzZ talk on the topic as part of the conference's "Developability of Bispecifics" program .
  • The presentation will take place Tuesday, Jan. 16 at 5:15 p.m. Pacific Time.
  • The BuzZ session will occur on Tuesday, Jan. 16, at 3:15 p.m. Pacific Time.
  • The Company uses its technology to advance candidates with partners and collaborators , and for its own proprietary pipeline .

ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants

Retrieved on: 
Monday, January 15, 2024

All authorized SARS-CoV-2 therapeutic antibodies that have been used in the clinic show severe to complete loss of virus neutralization potency against the currently circulating variants.

Key Points: 
  • All authorized SARS-CoV-2 therapeutic antibodies that have been used in the clinic show severe to complete loss of virus neutralization potency against the currently circulating variants.
  • ExeVir’s XVR012, a cocktail of XVR013m and XVR014, targets three distinct epitopes highly conserved across the broad sarbecovirus subgenus of Coronaviridae to minimize the risk for viral escape.
  • XVR013m is a heavy chain-only antibody targeting a unique membrane-proximal epitope in the S2 subunit of the spike protein.
  • ExeVir is currently gearing up to start the clinical development of both the combination XVR012, as well as its individual components XVR013m and XVR014.

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Retrieved on: 
Monday, January 8, 2024

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, provided a business update on portfolio programs.

Key Points: 
  • Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, provided a business update on portfolio programs.
  • The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for PRX012 for the treatment of AD.
  • Update on Financial Position for December 31, 2023
    At December 31, 2023, Prothena had cash, cash equivalents, and restricted cash of approximately $621 million.
  • Cash on hand provides sufficient capital which takes Prothena beyond the completion of its ongoing clinical trials.

ProMIS Neurosciences Issues Letter to Shareholders

Retrieved on: 
Monday, January 8, 2024

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that its Chief Executive Officer, Neil Warma, issued the following letter to the Company’s shareholders.

Key Points: 
  • TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that its Chief Executive Officer, Neil Warma, issued the following letter to the Company’s shareholders.
  • Our ultimate goal is to get these potential new drugs to patients who are in desperate need of safe and effective treatment options.
  • This specificity is expected to improve efficacy outcomes and prevent any off-target safety issues, which are common with other AD therapies currently marketed or in development.
  • As we navigate this transformative period, I am confident that ProMIS will emerge stronger, more resilient, and better positioned to make significant contributions to healthcare.

Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents

Retrieved on: 
Wednesday, January 3, 2024

Many immunocompromised people do not achieve full benefit from COVID-19 vaccines as their immune systems are unable to provide sufficient defense against SARS-CoV-2.

Key Points: 
  • Many immunocompromised people do not achieve full benefit from COVID-19 vaccines as their immune systems are unable to provide sufficient defense against SARS-CoV-2.
  • On December 18, 2023, Invivyd announced positive initial results from the ongoing CANOPY pivotal clinical trial.
  • VYD222 produced high serum virus neutralizing antibody (sVNA) titer levels against XBB.1.5 in the immunocompromised cohort.
  • If authorized, Invivyd aims to have VYD222 commercially available rapidly thereafter.